Secretory IgA Antigen Complexes for GI-Resistant Oral Allergy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for IgE-mediated allergies, such as food allergies, are inadequate due to limited efficacy and frequent adverse reactions, and there is a need for a therapeutic that can be orally administered and resistant to gastrointestinal degradation.
Innovation Solution
A composition of dimeric or secretory IgA complexed with preselected IgE-mediated antigen proteins, produced through recombinant human secretory component binding, is administered orally to treat allergies by forming immune complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional allergy treatments (avoidance diet, oral immunotherapy) are used, then some level of protection is achieved, but adverse reactions and anaphylaxis occur frequently
Solution Approach 1:
The patent uses secretory component as an intermediary molecule that binds to dimeric IgA and antigen complexes, creating a protective shield that prevents direct interaction between allergens and IgE antibodies on mast cells. This intermediary mechanism allows oral administration without triggering severe anaphylactic reactions while still providing effective allergy protection
Solution Approach 2:
The invention creates a composite therapeutic structure consisting of dimeric IgA molecules bound to secretory component and complexed with specific antigens. This composite formulation combines multiple functional elements (IgA for antigen binding, secretory component for stability and protection) to achieve both safety and efficacy in oral allergy treatment
2Reliability
If oral immunotherapy with food antigens is administered, then desensitization is achieved, but gastrointestinal degradation destroys the therapeutic molecules
Solution Approach 1:
The secretory component acts as a protective intermediary that shields the dimeric IgA-antigen complexes from gastrointestinal enzymes and degradation. This intermediary layer allows the therapeutic molecules to survive passage through the GI tract and reach the intestinal mucosa intact
Solution Approach 2:
The patent utilizes the unique biochemical properties of secretory component, which contains disulfide bonds and a specific structure that confers resistance to proteolytic degradation. This parameter change (adding secretory component) transforms the therapeutic molecule from GI-labile to GI-resistant, enabling oral administration
3Reliability
If monomeric IgA is used for therapy, then antigen binding is achieved, but resistance to gastrointestinal degradation is insufficient
Solution Approach 1:
The patent merges two IgA monomers into a dimeric structure linked by a J-chain, creating a more stable molecule with enhanced resistance to gastrointestinal degradation. The dimeric structure provides both antigen binding capability and improved stability, solving the contradiction between functionality and resistance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively treats IgE-mediated allergies by promoting regulatory T-cell responses and reducing allergic symptoms without disturbing normal metabolism, while also correcting dysbiosis in the microbiome.
Implementation Method 1
recombinant human secretory component binding
Data Source
AI summary
A composition is provided that includes dimeric IgA or secretory IgA that is complexed with a first preselected IgE mediated antigen protein. A method for treating a subject suffering from IgE mediated allergy is provided that includes administering the composition to a subject suffering from an allergy or sensitivity to the preselected IgE mediated antigen protein. The subject is readily treated simultaneously with more than one type of composition that vary in that the dimeric IgA or secretory IgA to complexed to a second a preselected IgE mediated antigen protein.